10 results about "Animal genome" patented technology

The invention discloses a universal molecular beacon kit for various animal-derived components, and belongs to the technical field of molecular biological detection. Aiming at gene segments with specific structural characteristics in 11 common livestock and poultry animal genomes, the invention designs a composition of a universal primer and a molecular beacon fluorescent probe. The combination can be used for carrying out real-time fluorescent PCR detection and melting curve analysis by using the kit and the method by taking genome DNA of a sample to be detected as a template. By comparing the shape of a melting peak of a detected sample and the characteristic melting temperature (Tm value) of the detected sample, 11 animal-derived components of livestock and poultry can be quickly and accurately identified under the condition of single-tube detection. Technical innovation is achieved in the field of molecular biological detection, an efficient and reliable solution is provided for animal-derived component detection, and the method has important practical value and popularization potential.

The invention belongs to the field of transgenic animals, and relates to an MET gene modified non-human animal. Specifically, the present invention provides a method of making a genetically modified non-human animal comprising modifying a non-human animal genome such that the modified non-human animal genome comprises a nucleotide sequence encoding a human or chimeric hepatocyte growth factor receptor (MET) protein. Also provided is a genetically modified non-human animal genome comprising a nucleotide sequence encoding a human or chimeric MET protein. The non-human animal obtained by the method provided by the invention provides a powerful tool for researching the function of the MET protein, and provides a platform for screening related drugs.

The present invention provides non-human animals expressing human CFB protein or chimeric (e.g., humanized) CFB protein and methods for using the same. The present invention further provides a non-human animal genome, a humanized CFB gene, and cells, tissues, organs, or non-human animals containing the non-human animal genome and the humanized CFB gene. The non-human animals obtained in this application successfully express human CFB protein or humanized CFB protein, which can be cleaved by CFD, bind to C3b, and exert similar effects in the human body. Furthermore, the non-human animals obtained in this application have complete renal function, normal blood biochemical indicators, and, more remarkably, do not exhibit the potential diseases observed in other transgenic mice known in this art.

Provided are a non-human animal with humanized IL22, IL22RA1, IL10RB, IL20RA, and / or IL20RB genes, or a genome thereof, and use thereof in the field of biomedicine. All or part of the endogenous IL22, IL22RA1, IL10RB, IL20RA, and / or IL20RB genes of the non-human animal are replaced by corresponding human regions to obtain a modified non-human animal genome. The non-human animal comprising the modified non-human animal genome can normally express human or humanized IL22, IL22RA1, IL10RB, IL20RA, and / or IL20RB proteins, and can be used as an animal model for studying the signal mechanism of IL22, IL22RA1, IL10RB, IL20RA, and / or IL20RB and screening drugs for related diseases, demonstrating application value for the research and development of new drugs targeting immune targets.

A method of modifying copy (1) and copy (2) of the β2-microglobulin (β2M) gene of a porcine donor animal, genetically modified porcine donor animal wherein copy (1) and copy (2) of the β2M gene of the porcine donor animal genome are modified, and a method of producing a donor porcine donor animal tissue or organ for xenotransplantation, wherein copy (1) and copy (2) of the β2M gene of the cells of said donor porcine donor animal are modified. A method of humanizing a genetically engineered donor animal by modification of the donor animal's expressed native β2-microglobulin protein through genetic alterations of the endogenous β2M genes, and as a result, the newly expressed β2M protein of the donor animal would contain some or all of the amino acids of the orthologous human β2-microglobulin (hβ2M) protein, in identity and orientation. This results in immune-compatible xenotransplants between donor animals and human recipients.

The invention relates to a method for constructing a retinitis pigmentosa (RP) animal model. The method comprises the step of introducing PRPF31 mutation into an animal genome. The invention also relates to the RP animal model constructed by the method and application of the animal model in evaluating the efficacy and / or safety of a gene therapy drug for treating RP in vivo.

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized MYOC locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized MYOC locus express a human myocilin protein or a chimeric myocilin protein, fragments of which are from human myocilin. Methods are provided for using such non-human animals comprising a humanized MYOC locus to assess in vivo efficacy of human-myocilin-targeting reagents and reagents for treating glaucoma.

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized stathmin-2 (STMN2) locus and methods of making and using such non- human animal genomes, non-human animal cells, and non-human animals are provided. Non- human animal cells or non-human animals comprising a humanized STMN2 locus express a human STMN2 mRNA and a human stathmin-2 or a humanized stathmin-2. Optionally, non- human animal genomes, non-human animal cells, and non-human animals can further comprise a mutated Tardbp locus. Methods are provided for using such non-human animals comprising a humanized STMN2 locus to assess agents as regulators of human STMN2 mRNA splicing. Agents that affect splicing of STMN2 mRNA may be useful as amyotrophic lateral sclerosis (ALS) therapeutics.

Provided herein are methods of generating a transgenic animal that include (a) generating an exogenous nucleic acid sequence, (b) inserting the exogenous nucleic acid sequence into a genome of an animal, wherein the exogenous nucleic acid sequence comprises a pair of site-specific recombinase recognition sequences, and wherein the exogenous nucleic acid sequence is introduced into the genome of the animal by using a gene-editing agent, thereby generating a transgenic animal, and optionally (c) delivering a transgene and a recombinase to the transgenic animal, wherein the transgene is integrated into the genome of the animal at a site of the site-specific recombinase recognition sequence, and wherein expression of the transgene is under control of an endogenous promoter of the gene locus, thereby altering somatic cells of the transgenic animal.

Genetically modified non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and / or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and / or NK cells, and in various in vivo screens.